Associated Medical Professionals of NY has been designated an Axonics Center of Excellence as well as a Bulkamid Center of Excellence. The designations recognize the A.M.P. team and specifically Hadley W. Narins, M.D., for her expertise with Axonics Therapy and Bulkamid, and sincere commitment to changing the lives of patients suffering from bladder and bowel dysfunction.

“Associated Medical Professionals of NY is proud to be recognized as a Center of Excellence for Axonics and Bulkamid. These designations are a testament to the dedication of our entire team, and in particular to Dr. Hadley Narins,” said Dr. Christoper M. Pieczonka, CEO of A.M.P. “We are committed to providing the best care to our patients and are extremely pleased to offer Axonics Therapy and Bulkamid.”

Today, millions of Americans suffer from overactive bladder and fecal incontinence.¹ Patients in Central New York with chronic and debilitating symptoms related to bladder and bowel dysfunction may seek treatment from the experts at A.M.P. Axonics Therapy gently stimulates the sacral nerve (sacral neuromodulation), restoring normal communication between the brain and the bladder. Axonics Therapy has been clinically proven to provide rapid and long-lasting relief of symptoms associated with bladder and bowel dysfunction.

In a clinical study, 129 patients with urgency incontinence were treated with Axonics Therapy. At 2-years, 93% of patients had successful therapy and 94% of patients were satisfied with their therapy.²

The Axonics Center of Excellence program recognizes highly trained and experienced physicians (typically urologists, urogynecologists, and colorectal surgeons) and clinical practices that are committed to patient education and providing exemplary care to achieve optimal clinical outcomes and patient satisfaction.

Dr. Hadley Narins also announced today the availability of Bulkamid— a minimally-invasive and long-lasting treatment option for bladder leaks caused by stress urinary incontinence (SUI)¹.

“We are pleased to offer Bulkamid to our female patients suffering from stress urinary incontinence. This innovative therapy has the potential to improve the quality of life of so many of our patients with just a quick and minimally invasive procedure. The therapy represents a new approach that may help women who were not helped by previous treatment options such as transvaginal mesh or urethral slings.” said Dr. Hadley Narins.

Bladder leakage is common in women, with 1 in 3 suffering from SUI at some point in their lives.² SUI tends to develop as women get older, often during or after pregnancy. The leaks are caused by weakness in the pelvic floor, preventing the urethra from closing fully when sudden pressure is put on the bladder. This can allow urine to leak out during normal daily activities such as coughing, laughing, exercising or lifting an object. Women who experience bladder leaks because of SUI can have severely decreased quality of life.

Bulkamid is a soft, water-based gel delivered via a series of small injections into the urethral wall. Once it is injected, the volume of the gel adds bulk to the urethra, supporting the closing mechanism of the urethra and providing better control of urine. Similar to some facial fillers, it remains in the body over time without causing reactions in the surrounding tissue, resulting in durable, long-lasting relief.

Benefits of Bulkamid:

• Safe and effective: In a clinical study, 92% of women reported being cured or improved³
• Simple procedure: A series of 3 – 4 small injections that takes just 10 – 15 minutes³
• Long-lasting symptom relief: Bulkamid is clinically proven to deliver symptom relief out to seven years⁴
• A more appealing treatment option: A majority of women with SUI chose Bulkamid before other surgical treatment options in a 2020 clinical study⁵

About Associated Medical Professionals of NY (A.M.P.)

Associated Medical Professionals of New York (A.M.P.) is a medical practice based in Syracuse serving the Central New York region. Established in 2008, A.M.P. has grown to become one of the largest groups of its kind in the area that strives to provide quality care at each of its nine offices and nine hospital locations. As a pivotal point of care in each community, A.M.P. is able to provide continuity of care for a vast population of patients. A.M.P. maintains a robust suite of services, including advanced urological care, robotic surgery, cancer care, radiation oncology, interventional radiology, pathology, lithotripsy, imaging and clinical research. For more information about A.M.P., visit www.ampofny.com.

About Axonics, Inc. and Sacral Neuromodulation

Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500™ following its No. 1 ranking in 2021.

Axonics sacral neuromodulation (SNM) systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults affected by fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

Axonics References

1. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132-1138.
2. Pezzella A, McCrery R, Lane F, et al. Two-year outcomes of the ARTISAN-SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system [in press]. Neurourol Urodyn. 2021.

Bulkamid References

1. Bulkamid Patient Information Leaflet
2. Magon, N et al. Stress urinary incontinence: What, when, why, and then what? J Midlife Health. 2011 Jul-Dec; 2(2): 57–64.
3. Itkonen-Freitas AM et al. Tension Free Vaginal Tape Vs Polyacrylamide Hydrogel Injection For Primary Stress Urinary Incontinence: A Randomized Controlled Trial. J Urol. Vol 203, 372 – 378, 2020.
4. Brosche et al. Seven-Year Efficacy and Safety Outcomes of Bulkamid for the Treatment of Stress Urinary Incontinence. Neurourol Urodyn. Vol 40(1):502-508, 2021.
5. Dwyer L et al. “Voice Your Choice”: A Study of Women’s Choice of Surgery For Primary Stress Urinary Incontinence. International Urogynecology Journal. 31:769–777, 2020